Sign In
Buy IVA
$4.04
-0.0500 (-1.22%)
At Close: Jun 03, 2026
Inventiva obtient un crédit d’un montant de 50 millions d’euros de la part de la Banque Européenne d’Investissement
06:00am, Monday, 16'th May 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 16 mai 2022 – Inventiva (Euronext Paris et Nasdaq : IVA) (la « Société »), société biopharmaceutique spécialisée dans le dévelop
Statement of total voting rights and shares forming the company’s share capital as of April 11, 2022
02:35pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Article R. 22-10-23 of the French Commercial Code
Information relative au nombre total de droits de vote et d’actions composant le capital social au 11 avril 2022
02:35pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Article R. 22-10-23 du Code de commerce
Combined General Meeting of May 19, 2022 - Availability of the preparatory documents
02:30pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), April 28, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral
Assemblée Générale Mixte du 19 mai 2022 - Modalités de mise à disposition des documents préparatoires
02:30pm, Thursday, 28'th Apr 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 28 avril 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société́ biopharmaceutique spécialisée dans le développement clinique de
Inventiva announces the presentation of a scientific abstract at the next International Conference on Fatty Liver
08:00pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), April 7, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral s
Inventiva annonce la présentation d’un abstract scientifique lors de la prochaine International Conference on Fatty Liver
08:00pm, Thursday, 07'th Apr 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 7 avril 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de pet
How Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)? Wall Street Analysts Think 166%
02:45pm, Tuesday, 05'th Apr 2022 Zacks Investment Research
The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA). While the effectiveness of this highly sought-after metric is que
How Much Upside is Left in Inventiva S.A. Sponsored ADR (IVA)?
12:03pm, Tuesday, 05'th Apr 2022
The average of price targets set by Wall Street analysts indicates a potential upside of 166.4% in Inventiva S.A. Sponsored ADR (IVA).
Inventiva announces filing of its 2021 Universal Registration Document and 2021 Annual Report on Form 20-F
09:44pm, Friday, 11'th Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, United States), March 11, 2022 – Inventiva (Euronext Paris and Nasdaq: IVA), a clinical-stage biopharmaceutical company focused on the development of oral
Inventiva annonce le dépôt de son Document d'Enregistrement Universel 2021 et de son Rapport Annuel 2021 (« Form 20-F »)
09:44pm, Friday, 11'th Mar 2022 GlobeNewswire Inc.
Daix (France), Long Island City (New York, Etats-Unis), le 11 mars 2022 – Inventiva (Euronext Paris et Nasdaq : IVA), société biopharmaceutique spécialisée dans le développement clinique de pet
Inventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript
07:35pm, Tuesday, 08'th Mar 2022 Seeking AlphaInventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript
02:35pm, Tuesday, 08'th Mar 2022
Inventiva S.A. (IVA) CEO Frédéric Cren on Q4 2021 Results - Earnings Call Transcript
The Daily Biotech Pulse: Moderna Outlines Steps For mRNA Tech Advancement, Voyager-Novartis Strike Licensing Deal, Valneva Reports Positive Chikungunya Shot Readout
01:00pm, Tuesday, 08'th Mar 2022 Benzinga
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks In Focus
Moderna Announces 4 Initiatives To Advance mRNA Vaccines As Preventative Options For Infectious Diseas
FDA Gives Green Signal To Inventiva''s Mid-Stage Lanifibranor Study In NASH Patients
11:22am, Tuesday, 08'th Mar 2022 Benzinga
The FDA has completed a safety review of Inventiva SA''s (NASDAQ: IVA ) IND application and signed off Phase 2 combination trial with its lead drug candidate, lanifibranor. The planned Phase 2 trial, LEGEND3, has been designed as a proof-of-concept trial to assess the safety … Full story available on Benzinga.com
